NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Parkinson's disease (PD) is a neurodegenerative disorder primarily characterized by motor impairments such as bradykinesia, tremor, and rigidity. Its neuropathological hallmarks include the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the aggregation of α-synuclein (α-syn) into Lewy bodies (LBs), which gradually spread to other central nervous system regions and peripheral tissues. The etiology of PD is multifactorial, involving a complex interplay of genetic predisposition, aging, environmental exposures, and lifestyle factors. Disease pathogenesis is predominantly driven by the synergistic action of core pathological mechanisms, including α-syn aggregation, oxidative stress (OS), mitochondrial dysfunction, and neuroinflammation. In recent years, the role of peripheral-central communication pathways in disease initiation and propagation has garnered significant attention. To date, pharmacotherapy remains the mainstay for improving the quality of life in PD patients. The most commonly used clinical agents primarily target the replenishment of depleted dopamine in the brain. However, these medications only alleviate symptoms and do not slow disease progression. This inherent limitation underscores the urgent need for more effective therapeutic strategies. This review aims to systematically outline the network of PD pathogenesis and the evolution of its treatment strategies, with a particular emphasis on a holistic perspective from etiology to therapy. It critically evaluates current bottlenecks in drug treatment and provides an in-depth analysis of potential candidate drugs for PD, as well as the latest advances in α-syn-targeted immunotherapies, iPSC-based regenerative therapies, and gene therapies. Building on this foundation, we further argue that the future of PD management must shift towards integrated, multi-target, and personalized therapeutic strategies to overcome existing efficacy barriers.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.